April 8, 2024
MOLCURE Inc.
Notice Regarding New Management Structure
MOLCURE Inc. today announced the following changes to its management structure effective April 8, 2024. Board Director and Chief Science Officer Satoshi Tamaki has been appointed as Representative Director, Chief Executive Officer, and Chief Scientific Officer. In tandem with this change, Representative Director and Chief Executive Officer Ryu Ogawa has been appointed as Board Director and Chief Innovation Officer.
| Name | New Title | Previous Title |
| Satoshi Tamaki | Representative Director, Chief Executive Officer, and Chief Scientific Officer | Board Director and Chief Science Officer |
| Ryu Ogawa | Board Director and Chief Innovation Officer | Representative Director and Chief Executive Officer |
■ Satoshi Tamaki, Ph.D.
Dr. Tamaki earned a Ph.D. in Media and Governance from Keio University Graduate School of Media and Governance, and a Masters of Science in Information Science from the Graduate School of Information Science at the Nara Institute of Science and Technology. His experience includes research positions at the Keio University Institute for Advanced Biosciences, and the Japan Society for the Promotion of Science. Since 2015 he has been the Board Director and Chief Science Officer at MOLCURE.
■ About MOLCURE Inc.
MOLCURE was founded in 2013 with a mission to build the best platform for biologics discovery in the world. Today, its platform integrates AI with evolutionary molecular engineering, next-generation sequencing, laboratory automation technologies, and a proprietary database containing more than one billion molecular entries. These capabilities enable the delivery of diverse, high affinity, specific and functional antibodies and peptides for researchers. MOLCURE is partnering with innovative companies to discover therapeutics with the potential to benefit patients around the world. For more information: https://molcure.com/
